Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIb, Randomized, Double-blind, Non-inferior, Multicenter Study to Evaluate the Safety and Immunogenicity of the Self-replicating Nanoparticle Carrier Replicon RNA Carrier (repRNA) Vaccine in Adults 18 to 65 Years of Age

NCT05542693 is registered in ClinicalTrials.gov with Azidus Brasil as lead sponsor.

NCT NCT05542693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05542693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIb, Randomized, Double-blind, Non-inferior, Multicenter Study to Evaluate the Safety and Immunogenicity of the Self-replicating Nanoparticle Carrier Replicon RNA Carrier (repRNA) Vaccine in Adults 18 to 65 Years of Age
Lead sponsor
Azidus Brasil
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2023
Completion date
September 30, 2023
Enrollment
300 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, covid-19 vaccine